# WIA-BIO-020 — Phase 3: Protocol > Regenerative-medicine canonical Phase 3: protocols (cell-prep + differentiation + implantation + vascularization + tumourigenicity-safety). # WIA-BIO-020: Regenerative Medicine Specification v1.0 > **Standard ID:** WIA-BIO-020 > **Version:** 1.0.0 > **Published:** 2025-12-26 > **Status:** Active > **Authors:** WIA Regenerative Medicine Research Group --- ## Table of Contents 1. [Introduction](#1-introduction) 2. [Stem Cell Types and Classification](#2-stem-cell-types-and-classification) 3. [Regeneration Mechanisms](#3-regeneration-mechanisms) 4. [Tissue Engineering and Scaffolds](#4-tissue-engineering-and-scaffolds) 5. [Growth Factor Delivery Systems](#5-growth-factor-delivery-systems) 6. [Clinical Applications](#6-clinical-applications) 7. [Regulatory Requirements](#7-regulatory-requirements) 8. [Implementation Guidelines](#8-implementation-guidelines) 9. [Safety Protocols](#9-safety-protocols) 10. [References](#10-references) --- ## 3. Regeneration Mechanisms ### 3.1 Cellular Regeneration Pathways #### 3.1.1 Proliferation **Cell Cycle Regulation**: ``` G1 → S → G2 → M → G1 ``` **Key Regulators**: - Cyclins (D, E, A, B) - CDKs (Cyclin-Dependent Kinases) - CDK inhibitors (p21, p27, p16) **Proliferation Rate**: ``` P = N₀ × e^(rt) ``` Where: - `P` = Cell population at time t - `N₀` = Initial cell number - `r` = Growth rate - `t` = Time #### 3.1.2 Differentiation **Lineage Commitment Factors**: - Transcription factors (RUNX2 for bone, PPARG for adipose) - Epigenetic modifications (DNA methylation, histone acetylation) - Signaling pathways (Wnt, BMP, Notch, Hedgehog) **Differentiation Efficiency**: ``` D_eff = (N_differentiated / N_total) × 100% ``` Target efficiency: >80% for clinical applications #### 3.1.3 Migration and Homing **Chemotactic Gradient**: ``` v = μ × ∇C ``` Where: - `v` = Migration velocity - `μ` = Chemotactic sensitivity - `∇C` = Concentration gradient **Homing Factors**: - SDF-1/CXCR4 axis - VEGF (Vascular Endothelial Growth Factor) - Selectins and integrins ### 3.2 Tissue Regeneration Rate **Mathematical Model**: ``` dT/dt = α × C × G - β × T ``` Where: - `T` = Tissue volume - `C` = Cell density - `G` = Growth factor concentration - `α` = Regeneration coefficient - `β` = Degradation coefficient **Integration Score**: ``` I = (V_integrated / V_total) × F_vascular × F_mechanical ``` Target integration score: I ≥ 0.8 ### 3.3 Angiogenesis (Blood Vessel Formation) **VEGF Signaling**: ``` VEGF + VEGFR2 → ERK1/2, Akt → Endothelial proliferation ``` **Vessel Density**: ``` D_vessel = N_vessels / Area (vessels/mm²) ``` Healthy tissue: 200-400 vessels/mm² **Sprouting Model**: ``` Tip cells → VEGF gradient Stalk cells → Lumen formation Pericytes → Vessel stabilization ``` --- ## 4. Tissue Engineering and Scaffolds ### 4.1 Scaffold Design Principles **Essential Properties**: 1. **Biocompatibility**: No toxic or inflammatory response 2. **Biodegradability**: Controlled degradation matching tissue growth 3. **Porosity**: 70-90% for nutrient diffusion 4. **Mechanical Strength**: Match native tissue 5. **Surface Chemistry**: Support cell adhesion ### 4.2 Scaffold Materials #### 4.2.1 Natural Polymers | Material | Source | Degradation | Applications | |----------|--------|-------------|--------------| | Collagen | Animal tissue | Enzymatic (MMP) | Skin, bone, cartilage | | Gelatin | Denatured collagen | Enzymatic | Drug delivery, wound healing | | Chitosan | Crustacean shells | Lysozyme | Cartilage, wound dressing | | Hyaluronic Acid | ECM | Hyaluronidase | Cartilage, dermal fillers | | Fibrin | Blood clotting | Plasmin | Wound healing, cell delivery | | Alginate | Seaweed | Non-enzymatic | Cell encapsulation | #### 4.2.2 Synthetic Polymers | Material | Type | Degradation Time | Applications | |----------|------|------------------|--------------| | PLA | Polyester | 12-24 months | Bone fixation, sutures | | PLGA | Copolymer | 1-12 months | Drug delivery, scaffolds | | PCL | Polyester | 24-36 months | Long-term implants | | PEG | Hydrophilic | Stable/tunable | Hydrogels, drug release | | PU | Polyurethane | Variable | Cardiovascular devices | ### 4.3 Scaffold Fabrication Methods **3D Printing (Bioprinting)**: ``` Resolution: 50-200 μm Print speed: 1-10 mm/s Cell viability: >85% post-print Layer thickness: 100-500 μm ``` **Electrospinning**: ``` Fiber diameter: 50 nm - 5 μm Voltage: 10-30 kV Flow rate: 0.1-5 ml/h Porosity: 70-95% ``` **Freeze Drying**: ``` Freezing: -20°C to -80°C Primary drying: -10°C, <100 mTorr Secondary drying: 20°C, <50 mTorr Pore size: 50-300 μm ``` ### 4.4 Scaffold Characterization **Porosity Measurement**: ``` P = (1 - ρ_scaffold / ρ_material) × 100% ``` **Pore Size Distribution**: 100-500 μm for bone, 50-150 μm for cartilage **Mechanical Testing**: ``` Young's Modulus (E) = σ / ε ``` Target values: - Bone: 10-20 GPa - Cartilage: 0.5-2 MPa - Skin: 0.1-1 MPa - Blood vessels: 1-10 MPa **Degradation Rate**: ``` M_remaining(t) = M₀ × e^(-kt) ``` Where: - `M_remaining` = Remaining mass - `M₀` = Initial mass - `k` = Degradation rate constant - `t` = Time --- ## 6. Clinical Applications ### 6.1 Cardiac Regeneration **Target**: Post-myocardial infarction (MI) heart repair **Cell Sources**: - iPSC-derived cardiomyocytes - Cardiac progenitor cells - MSCs (paracrine effects) **Delivery Methods**: - Direct injection into myocardium - Intracoronary infusion - Cardiac patch application **Protocols**: ``` Cell dose: 2-5 × 10⁸ cells Delivery timing: 2-4 weeks post-MI Growth factors: VEGF, FGF-2, IGF-1 Scaffold: Fibrin or alginate hydrogel ``` **Success Metrics**: - Ejection fraction improvement: >5% - Infarct size reduction: >15% - Vessel density increase: >30% ### 6.2 Neural Regeneration **Target**: Spinal cord injury, stroke, neurodegenerative diseases **Cell Sources**: - Neural progenitor cells (NPCs) - iPSC-derived neurons - Schwann cells (peripheral nerves) **Differentiation**: ``` iPSCs → Neural rosettes → NPCs → Neurons/Astrocytes/Oligodendrocytes ``` **Growth Factors**: - BDNF (Brain-Derived Neurotrophic Factor) - NGF (Nerve Growth Factor) - NT-3 (Neurotrophin-3) - GDNF (Glial-Derived Neurotrophic Factor) **Protocols**: ``` Cell dose: 5-10 × 10⁶ cells Injection: Intraspinal or intracerebral Scaffold: Hyaluronic acid or chitosan Immunosuppression: Cyclosporine or tacrolimus ``` **Success Metrics**: - Axon regeneration: >500 μm - Functional recovery: ASIA scale improvement - Electrophysiology: Restored conduction ### 6.3 Bone Regeneration **Target**: Non-union fractures, critical-size defects, osteoporosis **Cell Sources**: - BM-MSCs - Adipose-derived MSCs - Periosteal cells **Osteogenic Differentiation**: ``` MSCs + BMP-2 + Dexamethasone + β-glycerophosphate + Ascorbic acid → Osteoblasts → Mineralized matrix ``` **Scaffold Requirements**: - Material: Hydroxyapatite, β-TCP, PLGA - Porosity: 70-80% - Pore size: 200-400 μm - Compressive strength: >5 MPa **Protocols**: ``` Cell seeding: 5 × 10⁶ cells/cm³ BMP-2 dose: 100-200 μg Culture time: 7-14 days in vitro Implantation: Direct surgical placement ``` **Success Metrics**: - Bone volume/Total volume (BV/TV): >40% - Mechanical strength: >70% native bone - Complete bridging: 3-6 months ### 6.4 Cartilage Repair **Target**: Osteoarthritis, focal cartilage defects **Cell Sources**: - Autologous chondrocytes (ACI) - MSCs - iPSC-derived chondrocytes **Chondrogenic Differentiation**: ``` MSCs + TGF-β3 + BMP-6 + Dexamethasone → Chondrocytes → Collagen II, Aggrecan, SOX9⁺ ``` **Protocols**: ``` Cell dose: 1-5 × 10⁶ cells/cm² Scaffold: Collagen type I/III or hyaluronic acid Growth factors: TGF-β3 (10 ng/ml), BMP-6 (100 ng/ml) Implantation: Arthroscopic or open surgery ``` **Success Metrics**: - ICRS (International Cartilage Repair Society) score: ≥8/12 - Collagen II expression: >70% - GAG content: >60% native cartilage ### 6.5 Skin Regeneration **Target**: Burns, chronic wounds, diabetic ulcers **Cell Sources**: - Autologous keratinocytes - Fibroblasts - MSCs **Bioengineered Skin**: ``` Dermal layer: Fibroblasts + collagen scaffold Epidermal layer: Keratinocytes + fibrin glue Full-thickness: Bilayer construct ``` **Protocols**: ``` Cell expansion: 2-3 weeks Keratinocyte density: 5 × 10⁴ cells/cm² Fibroblast density: 1 × 10⁴ cells/cm² Growth factors: EGF, KGF, PDGF ``` **Success Metrics**: - Wound closure: >90% at 3 weeks - Scar formation: Minimal (Vancouver Scar Scale <5) - Pigmentation: Restored within 6 months --- ## 9. Safety Protocols ### 9.1 Pre-Clinical Testing Checklist - [ ] In vitro biocompatibility (ISO 10993) - [ ] Tumorigenicity assay (nude mice) - [ ] Biodistribution study - [ ] Toxicology (acute, subacute, chronic) - [ ] Immunogenicity assessment - [ ] Off-target differentiation check - [ ] Long-term genomic stability ### 9.2 Clinical Safety Monitoring **Adverse Events**: - Immune rejection - Infection - Tumor formation - Ectopic tissue formation - Thrombosis **Monitoring Schedule**: ``` Week 1: Daily Week 2-4: Every 3 days Month 2-6: Weekly Month 7-12: Monthly Year 2+: Quarterly ``` **Biomarkers**: - Complete blood count (CBC) - Liver function tests (ALT, AST) - Kidney function (creatinine, BUN) - Inflammation markers (CRP, IL-6) - Tumor markers (AFP, CEA, if applicable) ### 9.3 Dose Escalation **3+3 Design**: ``` Level 1: 1 × 10⁶ cells (3 patients) Level 2: 5 × 10⁶ cells (3 patients) Level 3: 1 × 10⁷ cells (3 patients) Level 4: 5 × 10⁷ cells (3 patients) ``` **DLT Criteria** (Dose-Limiting Toxicity): - Grade ≥3 adverse event - Serious adverse event (SAE) - Death within 30 days ### 9.4 Long-Term Follow-Up **Duration**: Minimum 5 years for cell therapy, 15 years for gene therapy **Assessments**: - Functional outcomes (disease-specific) - Quality of life (SF-36, EQ-5D) - Imaging (MRI, CT, ultrasound) - Biopsy (if indicated) - Genetic stability (karyotype, CGH array) --- --- ## A.1 Cell-preparation protocol Cell-preparation protocol covers the donor-screening envelope (FDA 21 CFR 1271 Subpart C eligibility determination + EU Directives 2004/23/EC + 2006/17/EC; KFDA Notification 2021-92 equivalents), the tissue-procurement envelope (informed consent + Institutional Review Board approval + chain-of-custody from the procurement site), the isolation envelope (mechanical + enzymatic dissociation as appropriate per cell source), the expansion envelope (passage limits per cell type — typically